EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Efficiency Gain and Early Toxicity Profile of Ultra—Versus Moderate-Hypofractionation: A Matched Real-World Comparison of the Two Current Standard Schedules for Adjuvant Breast Radiotherapy

Angela Barillaro, Mara Caroprese, Christina A. Goodyear, Emanuele Chioccola, Gianluca Valerio, Giuseppe Salzano, Caterina Oliviero, Stefania Clemente, Mauro Buono, Antonio Farella, Manuel Conson, Roberto Pacelli

Radiation · 2026-11-02 · 6 (4) · 43

DOI: 10.3390/radiation6040043 ↗
AbstractBibliografische Angaben

Abstract

Background: Ultra-hypofractionation (UHF) and moderate-hypofractionation (MHF) represent standard adjuvant radiotherapy (RT) schedules in breast cancer (BC). This study evaluates the departmental workflow impact and early physician-assessed toxicity kinetics of UHF compared to MHF in a matched real-world cohort. Methods: Patients receiving UHF (26 Gy in 5 fractions ± simultaneous boost) during the first year of institutional adoption were matched 1:1 with historical MHF patients (40.05 Gy in 15 fractions ± sequential boost). Departmental workflow metrics and treatment delays were evaluated. Physician-graded acute toxicities (CTCAE v5.0) were recorded at treatment completion (Day 0), Day 10, and Day 50 post-RT. Results: In total, 240 patients were analyzed. Transitioning to UHF coincided with enhanced efficiency, increasing adjuvant breast RT patient volume by 167% and reducing treatment delays (11% vs. 66%). UHF demonstrated lower G2 erythema at Day 0 (2% vs. 14%) and Day 10 (13% vs. 25%). Conversely, UHF exhibited higher G2 mastodynia (9% vs. 2%), oedema (10% vs. 3%) and G1 nipple–areola hyperpigmentation (NAC) (45% vs. 5%) at Day 10. Most acute toxicities were transient, becoming comparable between cohorts by Day 50. Conclusions: Implementing UHF coincided with efficiency gain without compromising overall acute safety. However, findings necessitate prospective translational validation. Personalization of radiotherapy in breast cancer remains a cornerstone of modern cancer care.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →